List of Excipients in Branded Drug PREZCOBIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	CELLULOSE, MICROCRYSTALLINE	2027-06-26
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	CROSPOVIDONE	2027-06-26
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	FERRIC OXIDE RED	2027-06-26
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	FERROSOFERRIC OXIDE	2027-06-26
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	HYPROMELLOSE	2027-06-26
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	MAGNESIUM STEARATE	2027-06-26
A-S Medication Solutions	PREZCOBIX	darunavir ethanolate and cobicistat	50090-1723	POLYETHYLENE GLYCOL	2027-06-26

Prezcobix Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Prezcobix is a fixed-dose combination tablet containing darunavir and cobicistat, marketed by Janssen Pharmaceuticals for the treatment of HIV-1 infection. Its excipient profile is conventional for an immediate-release, film-coated tablet, creating opportunities in generic development, excipient substitution, direct-compression optimization, pediatric and swallowability improvements, and regional supply-chain differentiation. The main technical constraint is maintaining bioequivalence for darunavir, a poorly water-soluble protease inhibitor, while preserving cobicistat’s pharmacokinetic boosting function.

What is Prezcobix and how is it regulated?

Prezcobix contains 800 mg of darunavir, administered as darunavir ethanolate, and 150 mg of cobicistat per tablet. The product is taken once daily with food and is used with other antiretroviral agents in adults and pediatric patients weighing at least 40 kg, according to the U.S. prescribing information.[1]

Attribute	Prezcobix
Active ingredients	Darunavir and cobicistat
Strength	800 mg/150 mg tablet
Dosage form	Immediate-release, film-coated tablet
Route	Oral
Developer and U.S. sponsor	Janssen Pharmaceuticals
FDA approval	January 29, 2015
Therapeutic area	HIV-1 infection
Pharmacologic role	Protease inhibitor plus pharmacokinetic enhancer
Administration	Once daily with food
Biologic product	No
Biosimilar pathway	Not applicable

Prezcobix is regulated as a small-molecule fixed-dose combination. Generic competitors would generally pursue an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act rather than a biosimilar application.

What is the FDA regulatory status of Prezcobix?

The product has FDA approval for use in combination with other antiretroviral agents. Its label includes warnings concerning hepatotoxicity, sulfa allergy, drug interactions, immune reconstitution syndrome, and renal monitoring when used with tenofovir.[1]

Cobicistat is a strong CYP3A inhibitor. It increases systemic exposure to darunavir but also creates a major drug-interaction burden. Excipient changes cannot alter the labeled interaction profile, but they can affect dissolution, food response, tablet integrity, and the consistency of exposure.

What excipients are used in Prezcobix tablets?

The U.S. product label identifies conventional tablet-core and film-coating excipients. The core includes microcrystalline cellulose, crospovidone, colloidal silicon dioxide, hypromellose, and magnesium stearate. The film coating includes hypromellose, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.[1]

Functional category	Prezcobix excipient examples	Primary technical function
Diluent and compression aid	Microcrystalline cellulose	Tablet mass, compactability, mechanical strength
Superdisintegrant	Crospovidone	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and blend uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Binder or film former	Hypromellose	Cohesion and coating formation
Coating polymer	Polyvinyl alcohol, hypromellose	Protective film and appearance
Plasticizer	Polyethylene glycol	Coating flexibility
Opacifier and color component	Titanium dioxide, talc	Appearance, opacity, surface properties

The excipient system indicates a conventional wet- or dry-processing tablet platform rather than a proprietary lipid formulation, amorphous solid dispersion, osmotic system, or modified-release technology.

How does the excipient system manage darunavir and cobicistat?

Darunavir has low aqueous solubility and is administered with food to improve absorption. Cobicistat is used at a relatively low dose but has a strong effect on CYP3A-mediated metabolism. The formulation therefore must deliver adequate dissolution of darunavir while maintaining dose uniformity for both active ingredients.

Darunavir formulation requirements

The main formulation risks are:

• Inadequate dissolution in gastrointestinal fluid
• Sensitivity to particle-size distribution
• Poor blend uniformity because of the large darunavir-to-cobicistat dose ratio
• Over-lubrication from magnesium stearate
• Compression-related dissolution delays
• Variability under fed and fasted conditions

Microcrystalline cellulose and crospovidone provide a standard platform for rapid tablet disintegration. Colloidal silicon dioxide improves flow and can reduce segregation in a high-dose blend. Magnesium stearate must be controlled because excessive lubrication can lower tablet tensile strength and delay wetting.

Cobicistat formulation requirements

Cobicistat is present at 150 mg and acts as a pharmacokinetic enhancer. Its formulation risks include blend uniformity, polymorphic or solid-state control, and potential interaction with the more abundant darunavir fraction during granulation or compression.

A generic developer would need to control:

1. Active-ingredient particle-size distribution.
2. Granule density and porosity.
3. Compression force.
4. Lubrication time.
5. Blend segregation during scale-up.
6. Dissolution similarity across multiple pH conditions.

The commercial value of an excipient strategy is therefore tied to reproducible bioequivalence, not simply replacement of a listed ingredient.

What formulation patents protect Prezcobix?

Prezcobix is protected through a combination of active-ingredient, combination-product, formulation, manufacturing, and method-of-use rights. The precise enforceable scope depends on the current U.S. patent register, Orange Book listings, prosecution history, terminal disclaimers, and any settlement agreements.

The principal patent risks for a generic developer are likely to fall into four groups:

Patent category	Potential scope	Commercial relevance
Darunavir composition patents	Active ingredient, salt, solvate, or crystalline form	May block use of darunavir or specific solid forms
Cobicistat composition patents	Active ingredient, intermediates, or solid forms	May delay independent use of cobicistat
Combination patents	Darunavir plus cobicistat in specified ratios or uses	Directly relevant to the fixed-dose product
Formulation and process patents	Tablet composition, manufacturing conditions, or dosage form	Relevant to excipient selection and design-around

A formulation patent may not require the exact branded excipient list. It may claim broad functional ranges, specific binders, disintegrants, coating systems, particle sizes, dissolution profiles, or manufacturing steps. Substituting hypromellose with another film former is not sufficient if a patent claims the final tablet by performance characteristics or broad excipient classes.

What is the Orange Book status of Prezcobix?

Prezcobix is an FDA-approved small-molecule product subject to Orange Book patent and exclusivity treatment. Generic applicants must address listed patents through a Paragraph I, II, III, or IV certification, depending on the patent and its expiration status.[2]

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The first substantially complete Paragraph IV applicant may qualify for 180 days of generic exclusivity if statutory conditions are met.

The practical patent questions are:

• Whether active-ingredient patents remain listed or enforceable.
• Whether combination or formulation patents remain relevant.
• Whether pediatric exclusivity has extended any listed patent term.
• Whether a generic product can avoid the claimed excipient combination.
• Whether the proposed manufacturing process creates infringement exposure.
• Whether a settlement restricts the launch date.

The Orange Book should be analyzed together with FDA approval letters, patent-term data, and the product’s regulatory exclusivity history. A listing alone does not establish ultimate validity or infringement.

When does Prezcobix lose exclusivity?

FDA approval occurred on January 29, 2015. Any new-drug exclusivity tied to the fixed-dose combination would have been separate from patent term and is not equivalent to market exclusivity for all components.[1,2]

The commercial launch date for a generic depends on the shortest effective barrier among:

• Patent expiration.
• Pediatric exclusivity.
• A successful Paragraph IV challenge.
• A settlement date.
• Regulatory review and tentative approval timing.
• Manufacturing readiness.
• Availability of darunavir and cobicistat active pharmaceutical ingredients.

Because Prezcobix combines two established active ingredients, its commercial barrier is more likely to depend on patent layering and formulation design than on a long period of standalone new chemical entity exclusivity.

What excipient substitution opportunities exist for generic manufacturers?

The strongest opportunities are in excipient equivalence and manufacturing efficiency, not in radical reformulation.

Direct-compression optimization

A manufacturer may evaluate co-processed microcrystalline cellulose, silicified microcrystalline cellulose, mannitol, dibasic calcium phosphate, or low-substituted hydroxypropyl cellulose as alternatives to portions of the existing filler system.

The objective would be to improve:

• Flow at high drug loading.
• Content uniformity.
• Tablet hardness at lower compression force.
• Disintegration after coating.
• Throughput and yield.
• Supply reliability across regions.

The principal risk is that a denser or less porous excipient can reduce dissolution even when disintegration remains within specification.

Superdisintegrant substitution

Crospovidone could potentially be compared with croscarmellose sodium or sodium starch glycolate. Each option changes swelling, wicking, granule structure, and dissolution behavior.

Crospovidone is attractive where rapid wicking and low gel formation are important. Croscarmellose sodium can provide strong swelling but may alter tablet water uptake and compactability. Sodium starch glycolate can be effective at low concentration but may produce greater sensitivity to processing and storage conditions.

Glidant and lubricant optimization

Colloidal silicon dioxide can be optimized through grade selection, concentration, and order of addition. Magnesium stearate can be replaced or partly reduced using sodium stearyl fumarate or other lubricants, subject to ejection force and stability data.

A lower-lubrication process could improve dissolution and tablet wetting. It may also increase tooling wear, sticking, or manufacturing variability.

Film-coating alternatives

The coating system creates a relatively accessible design-around area. Potential alternatives include:

• Hypromellose-based aqueous coating systems.
• Polyvinyl alcohol-based systems.
• Opadry-type premixes.
• Hypromellose phthalate or other enteric polymers, although enteric protection is not a stated requirement.
• Titanium-dioxide-free coatings for markets with restrictions on titanium dioxide.

A commercial opportunity exists for ready-to-use coating systems that match the product’s appearance, opacity, moisture protection, and mechanical durability while reducing coating time or solvent use.

What manufacturing and IP barriers affect excipient opportunities?

The primary manufacturing barrier is not the cost of individual excipients. It is the need to reproduce the product’s dissolution and exposure profile after changing excipient grade, supplier, or processing sequence.

High-risk process variables

Variable	Potential impact
Darunavir particle size	Dissolution and exposure
Cobicistat particle size	Blend uniformity and dose consistency
Granulation endpoint	Tablet porosity and disintegration
Lubrication time	Dissolution and mechanical strength
Compression force	Porosity, hardness, and disintegration
Coating weight gain	Moisture protection and dissolution
Excipient moisture	Stability and processability
Milling conditions	Solid-state properties and flow

Excipient suppliers can capture value by offering controlled grades with narrower particle-size distributions, documented elemental impurity profiles, low endotoxin levels, and validated performance across multiple manufacturing sites.

The strongest supplier proposition is a qualified dual-source platform that reduces dependence on a single excipient manufacturer without changing the finished-product performance profile.

Which companies are positioned to challenge Prezcobix?

Potential challengers include large generic manufacturers with HIV portfolios, regional antiretroviral suppliers, and contract development and manufacturing organizations with experience in high-dose immediate-release tablets.

Relevant competitive capabilities include:

• Access to darunavir and cobicistat APIs.
• Experience with fixed-dose antiretroviral combinations.
• FDA ANDA filing capability.
• Ability to conduct comparative dissolution and bioequivalence studies.
• Capacity to manage Paragraph IV litigation.
• Low-cost manufacturing in India, China, Eastern Europe, or Latin America.
• Government and tender-market access.

HIV products are often purchased through public-health programs, tenders, and institutional channels. This favors manufacturers with reliable supply, WHO prequalification or equivalent regulatory credentials, and competitive cost structures.

What commercial opportunities exist beyond a conventional generic?

Pediatric dosage forms

The adult 800 mg/150 mg tablet is intended for patients weighing at least 40 kg. Lower-strength tablets, dispersible tablets, oral granules, or multiparticulate formulations could address younger or lower-weight patients, subject to regulatory and clinical requirements.

Excipient opportunities include:

• Taste-masking systems.
• Reduced tablet size.
• Rapidly dispersible matrices.
• Low-swelling polymers.
• Sugar-free and alcohol-free liquid systems.
• Flexible-dose multiparticulates.

Regional excipient compliance

A titanium-dioxide-free coating, lactose-free formulation, or formulation using regionally available excipients may improve market access. Excipients with established compendial status in the target jurisdiction reduce regulatory risk.

Supply-chain resilience

A qualified alternative to a single-source coating polymer, lubricant, or colloidal silicon dioxide grade can protect production continuity. This is valuable for public-sector procurement, where stock-outs can affect treatment programs and trigger emergency sourcing.

Sustainability and process economics

A lower-solvent aqueous coating process can reduce environmental controls and operating cost. Direct compression may reduce equipment requirements and batch time, but only if blend uniformity and dissolution remain robust.

How does Prezcobix compare with competing HIV fixed-dose products?

Product	Active ingredients	Formulation implication	Excipient opportunity
Prezcobix	Darunavir/cobicistat	High-dose protease inhibitor tablet	Generic substitution, coating, pediatric formats
Symtuza	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide	More complex four-drug fixed-dose tablet	Greater blend and stability complexity
Prezcobix plus NRTI backbone	Darunavir/cobicistat with separate agents	Multiple-tablet regimen	Packaging and adherence differentiation
Darunavir/ritonavir regimens	Darunavir plus ritonavir	Different booster and interaction profile	Less direct excipient comparability
Other integrase-based combinations	Integrase inhibitor plus NRTIs or booster	Often lower formulation complexity	Stronger competitive pressure on convenience and tolerability

Prezcobix competes commercially with newer single-tablet regimens, especially integrase inhibitor-based products. Its strongest generic opportunity is in price-sensitive markets where darunavir’s resistance profile and treatment history remain commercially relevant.

What litigation and settlement issues affect generic entry?

A generic applicant may face patent litigation within 45 days after the sponsor receives notice of a Paragraph IV certification. A filing can trigger a statutory stay of FDA approval for up to 30 months, subject to court decisions and statutory exceptions.[2]

Settlement agreements may provide:

• A specified licensed launch date.
• Authorized-generic supply rights.
• Restrictions on formulation or manufacturing.
• Allocation of litigation costs.
• Covenants not to sue for particular products.
• Conditions tied to patent validity or regulatory approval.

For Prezcobix, an excipient design-around can reduce infringement exposure, but it does not eliminate risk if patents claim the active combination, broad tablet architecture, or dissolution performance.

How strong is the Prezcobix patent estate?

The estate should be viewed as layered rather than dependent on one excipient patent. Active-ingredient and combination claims generally create a stronger barrier than ordinary coating or filler claims. Formulation patents become commercially important when they cover the specific fixed-dose ratio, dissolution profile, or manufacturing process used by the product.

From a business perspective:

Estate layer	Relative risk to generic entry
Active-ingredient claims	High if unexpired and enforceable
Combination claims	High for the exact darunavir/cobicistat product
Formulation claims	Medium to high, depending on claim breadth
Manufacturing claims	Medium, with design-around potential
Excipients listed in the label	Low by themselves
Method-of-use claims	Variable; depends on indication and labeling
Trade dress and product appearance	Low for FDA approval, but relevant commercially

A generic developer should prioritize non-infringing formulation architecture, not merely an ingredient-by-ingredient substitution.

Key Takeaways

• Prezcobix is an immediate-release darunavir/cobicistat tablet approved by the FDA in 2015.
• Its excipients are conventional: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, hypromellose, magnesium stearate, and standard film-coating materials.
• The core technical challenge is maintaining darunavir dissolution and exposure after excipient or process changes.
• The most practical commercial opportunities are generic tablets, coating-system substitution, dual-source excipient qualification, pediatric formats, and regional formulations.
• Prezcobix is a small-molecule product, so biosimilar competition is not relevant.
• Paragraph IV strategy depends on the current Orange Book record, patent claims, prosecution history, and any settlement terms.
• Excipient substitution can support a design-around, but label matching alone does not establish freedom to operate.
• Competition from integrase inhibitor-based single-tablet regimens limits the long-term premium opportunity for Prezcobix.

FAQs About Prezcobix Excipients and Commercial Strategy

Can a generic manufacturer use different excipients from Prezcobix?

Yes. An ANDA product generally does not need to replicate every inactive ingredient, but it must satisfy regulatory requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and labeling. The alternative excipient system must not compromise dissolution, stability, or manufacturing consistency.[2]

Is Prezcobix a biologic that can face biosimilar competition?

No. Prezcobix contains chemically synthesized small-molecule active ingredients. Competition would proceed through generic-drug pathways rather than the biosimilar pathway.

Does Prezcobix require an amorphous solid dispersion?

The public product labeling identifies a conventional film-coated tablet and does not describe an amorphous solid-dispersion platform.[1] Darunavir solubility and dissolution still require close control during generic development.

Could a titanium-dioxide-free Prezcobix formulation be commercially viable?

Yes. A titanium-dioxide-free film coating could be developed for jurisdictions or customers that restrict or prefer to avoid titanium dioxide. The replacement coating must preserve appearance, opacity, mechanical durability, and stability.

Is a liquid Prezcobix formulation an attractive opportunity?

It could address swallowing and pediatric needs, but the formulation would face taste, chemical stability, dose-uniformity, preservative, packaging, and drug-interaction labeling requirements. A dispersible tablet or multiparticulate format may offer a simpler development path than a liquid.

References

1. Janssen Pharmaceuticals, Inc. (2023). Prezcobix (darunavir and cobicistat) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug product and patent certification requirements under the Hatch-Waxman Act. U.S. Department of Health and Human Services.

4. World Health Organization. (2022). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. World Health Organization.